Swedish biotech Anocca AB raised approximately $46 million (SEK 440 million) to advance its CRISPR-edited T-cell receptor (TCR) therapy, VIDAR-1, in Phase I clinical trials for pancreatic ductal adenocarcinoma targeting KRAS mutations. VIDAR-1 is the first nonviral genome-edited TCR therapy entering clinical development in Europe. The funds will also support the progression of Anocca’s broader pipeline aimed at expanding precision cell therapies across oncology indications with cost-effective discovery and manufacturing platforms.